ALX Oncology Holdings Inc (ALXO): Operating Cash Flow
-$84.14M
Year ended 2025-12-31
-$70.78M
Trailing 12 months to 2026-06-30
| Period ended | Operating Cash Flow | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$84.14M | n/m | 2026-03-09, From 2025-01-01 |
| 2024-12-31 | -$121.91M | n/m | 2026-03-09, From 2024-01-01 |
| 2023-12-31 | -$130.36M | n/m | 2026-03-09, From 2023-01-01 |
| 2022-12-31 | -$89.22M | n/m | 2025-03-06, From 2022-01-01 |
| 2021-12-31 | -$68.10M | n/m | 2024-03-07, From 2021-01-01 |
| 2020-12-31 | -$38.29M | n/m | 2023-03-09, From 2020-01-01 |
| 2019-12-31 | -$14.25M | n/m | 2022-02-28, From 2019-01-01 |
| 2018-12-31 | -$13.19M | n/a | 2021-03-18, From 2018-01-01 |
Operating Cash Flow at similar companies
| Company | Year ended | Operating Cash Flow | Change YoY |
|---|---|---|---|
| ALX Oncology Holdings Inc (ALXO) | 2025-12-31 | -$84.14M | n/m |
| Scynexis Inc (SCYX) | 2025-12-31 | -$5.28M | n/m |
| Rani Therapeutics Holdings, Inc. (RANI) | 2025-12-31 | -$18.71M | n/m |
| Biomea Fusion, Inc. (BMEA) | 2025-12-31 | -$70.37M | n/m |
| Palvella Therapeutics, Inc. (PVLA) | 2025-12-31 | -$25.01M | n/m |
| ProPhase Labs, Inc. (PRPH) | 2025-12-31 | -$8.34M | n/m |
| Pasithea Therapeutics Corp. (KTTA) | 2025-12-31 | -$15.21M | n/m |
| Rockwell Medical, Inc. (RMTI) | 2025-12-31 | -$659.0K | n/m |
| DiaMedica Therapeutics Inc. (DMAC) | 2025-12-31 | -$29.06M | n/m |
Compare ALXO, SCYX, RANI, BMEA side by side · Screen every company in Pharmaceutical Preparations ↗